|
|
Via Fratelli Cervi, Centro Direzionale di Milano 2
Palazzo Vasari, Segrate (MI) 20090 Italy
phone:+(39) 02-2104951
fax:+39 02 21049 529
|
|
| Symbol |
BXLN |
| Exchange |
SWX |
| Founded |
2002 |
| Employees |
50 |
|
|
| www.bioxell.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals for Urology, Inflammation, and Other Applications |
|
| Management |
| Francesco Sinigaglia, MD, Chief Executive Officer, co-founder and Managing Director; Niels Ackermann, CFA, Chief Financial Officer; Bertrand Lehuu, Chief Business Officer; Alvise Sagramoso, Chief Administrative Officer; Milan Uskokovic, PhD,
Vice President of Medicinal Chemistry; Daniele DAmbrosio, MD, PhD, Director Preclinical Research and Development, associate founder; Alessandra Orlandi, CMC & Supplies Director; Paola Panina-Bordignon, PhD, Director of Preclinical Research, associate founder
|
| |
|
|
|
|
|
|
|
| Keywords |
| urology, inflammatory, diseases, chronic, vitamin, bioxell, pain, pharmaceuticals |
|
|
|
| Description |
|
BioXell is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for applications in urology, inflammation-related disorders, pain, osteoporosis, and hyperparathyroidism. |
|
| Products / Services |
BioXell's lead product candidate, Elocalcitol, is in clinical development for three indications. The company received positive results from its completed phase IIb trial of Elocalcitol for Benign Prostatic Hyperplasia (BPH), is finishing its Phase IIb trial for Overactive Bladder (OAB), and commenced a Phase II trial in male infertility in late 2007. Its inflammatory treatment product pipeline includes: BXL746, an anti-inflammatory medication currently in Phase IIa trials in post-surgical adhesions; and TREM-1, in preclinical development for the treatment of sepsis and being researched for potential use in Inflammatory Bowel Disease (IBD). MNAC13 is currently in preclinical development for pain treatment, with entry into humans expected in 2009. Additionally, BXL093 is a preclinical candidate for the treatment of osteoporosis. The company also pursues product-oriented partnerships to acquire or in-license complementary drug candidates within its areas of focus and to leverage non-core programs into profitable partnerships.
|
|
| Technology / Differentiation |
| BioXell uses three technology platforms in the development of its pharmaceuticals. First, VD3 (Vitamin D3) analogues are secosteroid hormones that play an important role in regulating calcium and bone metabolism, cell proliferation and differentiation, as well as the overall immune response. They are currently found in Elocalcitrol and BXL746. TREMs (Triggering Receptors Expressed on Myeloid cells) are a family of receptors believed to play a significant role in various inflammatory conditions, such as septic shock, multiple sclerosis and asthma. TREM-1 has been demonstrated to work as an early, central player in the inflammatory cascades following bacterial and fungal infections, indicating a potential role for TREM-1 antagonists in the treatment of devastating acute inflammatory reactions. BioXell has also developed an anti-TrkA antibody, MNAC13, which may become a promising alternative to current pain treatments like morphine or COX-2 inhibitors. TrkA is the high affinity receptor for NGF (Nerve Growth Factor); the binding of NGF to TrkA appears to determine the degree of inflammation and pain. The MNAC13 antibody thus antagonizes the action of NGF by binding to TrkA receptors. |
|
| Market / Customers |
The company's products are expected to be competitive in a variety of markets representing millions of individuals and billions in revenue. The commercial potential of Elocalcitol alone is expected to be $7 billion in seven major pharmaceutical markets.
|
|
| Status |
| From 2005 to 2007, BioXell collaborated with Merck in the development of TREM-related therapeutic and diagnostic products for sepsis. The company regained the rights to the TREM platform after that period and will soon search for a new development partner. Additionally, BioXell is planning to conduct phase III trials of Elocalcitrol in BPH and-pending the results of phase II trials in male infertility-will organize a large scale pivotal trial to measure the effects of Elocalcitol on the success rate of in vitro fertilization. The company is also investigating the application of VD3 analogues for additional therapeutic indications, including chronic obstructive pulmonary disease, endometriosis, hypertension, and superficial bladder cancer (among others). |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
